[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"learning\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:learning":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,51,76,101,134,165,196,272,297,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100651587","brain-stimulation-paired-with-structured-language-learning-in-adults-100651587",false,"NCT07762118","Brain Stimulation Paired With Structured Language Learning in Adults","A Study of Transcranial Electrical Stimulation (tES) Paired With Structured Learning Protocols for Accelerated Skill Acquisition: Sub-Protocol A (Adult Language Learning)","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Able to understand the consent materials and the informed consent process in English, or in another language for which an IRB-approved consent form is available\n* Willing and able to participate in structured language-learning activities for the duration of the intervention period\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* History of epilepsy or any seizure disorder\n* Active skin disease, open wounds, or significant skin irritation at electrode contact sites\n* Implanted electronic medical devices where stimulation would be contraindicated per device manufacturer guidance or investigator judgment after individual risk assessment\n* Significant cognitive impairment that would interfere with informed consent or study participation\n* Any other condition that, in the investigator's judgment, would compromise participant safety or the integrity of the study data",true,"ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study investigates whether transcranial electrical stimulation (tES) delivered during structured language-learning sessions affects the rate and quality of second-language acquisition in adults.\n\nAdults who are learning or planning to learn a new language are randomly assigned in equal numbers to receive either active stimulation or sham (placebo) stimulation while completing structured language-learning content. Participants wear a non-invasive transcranial electrical stimulation headset that delivers a low-level electrical current through electrodes resting on the scalp, targeting cortical regions associated with language. Sessions typically last 20 to 30 minutes and may be completed at home or in person at a participating language program.\n\nLanguage proficiency is measured with a standardized assessment before and after the intervention period, with additional app-derived performance metrics and participant-reported measures collected throughout. A follow-up assessment may be conducted up to 12 months after the intervention ends to evaluate whether any observed effects persist.\n\nIn this study the device is applied as a learning aid in healthy adults. It is not used to diagnose, treat, cure, or prevent any disease.",[27,28],"Language Development","Learning",[30,31,32,33,34,35,36,37],"transcranial electrical stimulation","tES","transcranial direct current stimulation","tDCS","second language acquisition","language learning","neuromodulation","healthy volunteers","RECRUITING","2026-08-07",{"date":41,"type":42},"2026-08-13","ACTUAL",{"date":44,"type":21},"2026-09-01",{"date":46,"type":21},"2032-06-01",{"name":48,"class":49},"General Neuro Inc.","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100649680","effects-of-a-familiarization-protocol-on-time-to-exhaustion-performance-100649680","NCT07735507","Effects of a Familiarization Protocol on Time to Exhaustion Performance","Effects of a Familiarization Protocol on Time to Exhaustion Performance Treadmill Running Protocol","Inclusion Criteria:\n\n* healthy and physically active\n\nExclusion Criteria:\n\n* current or recently injured participants","40 Years",{"count":60,"type":21},20,[24],"Familiarization is widely recommended before exercise performance testing to improve measurement consistency and reduce learning effects. However, practical constraints often limit researchers to a single-or no-familiarization session, raising the possibility that improvements observed following an intervention may partially reflect increased familiarity with the testing procedure rather than genuine physiological adaptations. This issue may be particularly relevant for time-to-exhaustion (TTE) protocols, which have been reported to exhibit greater between-session variability than self-paced endurance tests.\n\nThis exploratory analysis examined the magnitude of the familiarization effect during treadmill TTE testing by comparing a familiarization trial with a subsequent experimental trial. Linear mixed-effects models will be used to evaluate changes in TTE performance while accounting for pre-exercise fatigue and recovery, and between-session agreement was assessed using intraclass correlation coefficients and Bland-Altman analysis.",[28],[65],"familiarization","NOT_YET_RECRUITING","2026-07-24",{"date":69,"type":42},"2026-07-30",{"date":44,"type":21},{"date":72,"type":21},"2027-01-30",{"name":74,"class":75},"University of Maia","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":50},"100647422","application-of-the-ai-platform-iln-based-on-deepseek-in-the-teaching-of-lupus-nephritis-100647422","NCT07706998","Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis","Inclusion Criteria:\n\n* As a student majoring in clinical medicine\n* Volunteering to participate in the study\n\nExclusion Criteria:\n\n* Inability to understand, read, or communicate in Chinese\n* Failure to participate in any stage of the study (e.g. in-class education session, or post-test)\n* Requesting withdrawal from the study",{"count":83,"type":21},50,[24],"Aim:\n\nTo evaluate the application effect of the teaching platform iLN in the teaching of lupus nephritis, aiming to provide practical experience and evidence-based support for the implementation of generative AI technology in professional medical education.\n\nMethod:\n\nBased on the DeepSeek large language model, the investigators developed \"iLN\" - an interactive teaching platform for lupus nephritis. This platform integrates the latest authoritative textbooks, clinical guidelines, pathological atlases, and real clinical cases, and includes seven core modules, such as \"case interaction\", \"knowledge teaching\", and \"AI question answering\". The investigators conducted a randomized controlled trial (RCT) on 50 fourth-year undergraduate students from Nanjing University School of Medicine to evaluate the effectiveness of the iLN platform compared to traditional teaching methods. The teaching effect was evaluated through objective test scores and questionnaires about student satisfaction and platform usability.",[28],[88,89,90,91],"Generative artificial intelligence","DeepSeek","Lupus nephritis","Medical education","2026-07-15",{"date":94,"type":42},"2026-07-16",{"date":96,"type":21},"2026-07-01",{"date":98,"type":21},"2026-12-31",{"name":100,"class":75},"Nanjing University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":50},"100634946","enhancing-letter-speech-sound-learning-and-reading-network-activation-with-transcranial-electrical-stimulation-100634946","NCT07546292","Enhancing Letter-Speech Sound Learning and Reading Network Activation With Transcranial Electrical Stimulation","Transcranial Electrical Stimulation and the Reading Brain: Toward Novel Interventions for Reading Impairments","LexiStim","Inclusion Criteria:\n\n* Age 18-35\n* All genders\n* Written informed consent by the participant\n* German speaking (native)\n* Right-handed\n\nExclusion Criteria:\n\n* Diagnoses of neurological disorders, intellectual disabilities, or psychiatric disorders (We do not exclude participants with common comorbidities of dyslexia, specifically dyscalculia, Attention Deficit\u002FHyperactivity Disorder, or Autism Spectrum Disorders)\n* History of any acquired brain damage or evidence of fetal alcohol syndrome\n* Hearing problems and vision problems that cannot be corrected\n* Inability to follow procedures or understand the instructions given in (Swiss-)German\n* Current use of psychoactive medications or substances, or a history of substance abuse that may affect brain function, performance or MRI signal quality\n* A nonverbal IQ \\\u003C 80\n* Having previously participated in a transcranial electrical stimulation study\n* Knowledge to read or write in a language using foreign letters (i.e., different from the Latin alphabet)\n* Contraindications to brain stimulation or MRI, such as: History of epilepsy or severe migraine; Skull breach such as craniotomy; Wearing neurostimulators or cardiac pacemakers; Wearing hearing aid devices or cochlear implants, which are not MR safe; Having metal pieces in their body (e.g., piercings that cannot be removed and contain metal, screws or plates from surgical operations, wounds from metal splinters or similar); Claustrophobia or problems lying in the scanner (e.g., pain, anxiety); Previous surgery on the head or heart; Being pregnant (a pregnancy test will be conducted at the MR center before the measurement if a female participant suspects she might be pregnant or is uncertain about her pregnancy status according to the Swiss Ethics Leitlinie:\n\nhttps:\u002F\u002Fswissethics.ch\u002Fassets\u002Fpos\\_papiere\\_leitfaden\u002F20110906\\_kek\\_mri.pdf); Having problems lying still (strong cold, tremor, etc.); Wearing non-removable dental braces","35 Years",{"count":20,"type":21},[24],"This study investigates the effects of transcranial electrical stimulation (tES) on the brain and its potential to enhance reading-related learning. Adult participants with a range of reading abilities will receive transcranial random noise stimulation (tRNS) while they perform an artificial orthography learning task. This task simulates letter-speech sound learning, an important first step during reading acquisition known to be impaired in individuals with developmental dyslexia. The effects of the intervention will be assessed using both behavioral measures and functional magnetic resonance imaging (fMRI).",[114,115,116,28,117],"Dyslexia, Developmental","Reading","Dyslexia","Learning Disabilities",[116,119,30,120,36,121,122,123,124],"tRNS","non-invasive brain stimulation","reading","functional magnetic resonance imaging","fMRI","audiovisual-learning","2026-05-19",{"date":127,"type":42},"2026-05-22",{"date":129,"type":42},"2026-04-23",{"date":131,"type":21},"2027-06",{"name":133,"class":75},"Silvia Brem",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":50},"100613512","phase-4-dual-orexin-antagonism-and-emotion-and-affective-processing-study-100613512","NCT07267559","Dual Orexin Antagonism and Emotion and Affective Processing Study","An Investigation of the Effects of Dual Orexin Antagonism on Emotional Processing and Learning in Healthy Individuals","DOREA","Inclusion Criteria:\n\n* Adult participant, aged 18 to 40 years\n* Willing and able to give informed consent for participation in the trial\n* Able to follow study procedures as laid out in the participant information sheet\n* Able to read and understand English\n* Willing to avoid drinking alcohol, using recreational drugs, drinking grapefruit juice 24 hours before and after the study visit\n* Willing to avoid driving or engaging in any activities requiring full alertness (e.g. cycling or operating heavy machinery) until the morning after the study visit day.\n* Able to complete computer tasks without eye glasses even if uses correction regularly\n\nExclusion Criteria:\n\n1. History of, receiving or seeking treatment for any sleep or circadian rhythm disorder or positive in screening questionnaires.\n2. History of, receiving or seeking treatment for any clinically significant mental health condition (including but not limited to schizophrenia, psychosis, bipolar affective disorder, major depressive disorder, obsessive compulsive disorder, post-traumatic stress disorder) or positive in screening questionnaires.\n3. History of, or current medical condition(s) which might increase the risk of oral administration of daridorexant, including:\n\n   * ADHD requiring treatment with stimulants or other centrally-acting drugs\n   * Neurological problems, including traumatic brain injury, epilepsy, Central Nervous System tumours or other severe neurological problems (e.g. Parkinson's disease; blackouts requiring hospitalisation)\n   * Current Asthma, Chronic Obstructive Pulmonary Disease, emphysema or any medical condition that affects the lungs or breathing\n   * Mild to severe hepatic impairment (Child-Pugh class A-C)\n   * Severe renal disease\n   * Severe gastrointestinal problems\n   * History of, or current medical condition(s) which, in the opinion of the Investigator may interfere with the safety of the participant or the scientific integrity of the study\n4. Pregnancy (as determined by urine pregnancy test taken during screening visit), intention to become pregnant or breastfeeding during the study or over the following six months.\n5. Body mass index (BMI) below 18 or above 30kg\u002Fm2.\n6. Current or past history of drug or alcohol dependency.\n7. Regular alcohol consumption of more than 21 units per week or use of recreational drugs or performance-enhancing drugs (e.g. cannabis, cocaine, amphetamines) within past three months.\n8. Excessive caffeine consumption, i.e., consumption higher than 400mg a day of caffeine. This corresponds to more than 4 cups of brewed coffee, 6 espressos or filtered coffees, 9 cups of black tea, 10 cans of cola, or two \"energy shot\" drinks.\n9. Smoking more than 5 cigarettes per day (or other nicotine replacement equivalent, including vaping on average more than 50 puffs a day).\n10. Current or recent (past two months) use of any medication or medical devices (e.g. implanted neurostimulator) that affect brain function for the exception of contraceptives (pill, the Depo-Provera injection or the progesterone implant). This includes drugs that cause sedation (e.g. benzodiazepines, opioids, tricyclic antidepressants or sedative antipsychotics) or antihistamines.\n11. Current use of any medications at risk of interaction with daridorexant; in particular:\n\n    * strong or moderate CYP3A inhibitors (e.g. strong inhibitors - itraconazole, clarithromycin, ritonavir, grapefruit juice; moderate inhibitors - fluconazole, verapamil, diltiazem, erythromycin, ciprofloxacin, cyclosporine)\n    * strong or moderate CYP3A inducers (e.g. of strong inducers - rifampicin, carbamazepine, St. John's wort; moderate inducers - bosentan, efavirenz, etravirine, modafinil)\n    * Gastric pH-modifiers (e.g. famotidine and proton pump inhibitors such as omeprazole)\n    * P-gp transporters (e.g. dabigatran, digoxin)\n12. Inability to ingest up to 95mg of lactose.\n13. Previous participation in any other drug study or sleep intervention study in the last three months.\n14. Previous participation in any other study by the Psychopharmacology and Emotion Research lab (Department of Psychiatry, University of Oxford) or which uses the same computer tasks in the last 6 months\n15. Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator.",{"count":143,"type":21},62,[145],"PHASE4","In this study, the investigators will examine the effects of blocking the orexin system on human behaviour and brain function using daridorexant, a medication that inhibits orexin activity. Orexin is a brain chemical involved in regulating sleep, emotion, motivation, and stress responses, which are often disrupted in mental health disorders. Healthy volunteers will be randomly assigned to receive a single dose of daridorexant or placebo in a double-blind design. Participants will then complete behavioural and cognitive tasks assessing emotional processing, aversive learning, and executive function. The study aims to clarify the role of orexin in emotional and cognitive processes relevant to conditions such as depression and anxiety.",[28,148,149],"Cognitive Functioning","Emotional Processing",[151,152,153,154,28,155],"Drug","Orexin","Hypocretin","Healthy volunteers","Cognition","2026-03-16",{"date":158,"type":42},"2026-03-19",{"date":160,"type":42},"2025-10-01",{"date":162,"type":21},"2026-10-01",{"name":164,"class":75},"University of Oxford",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100415814","remediation-program-via-a-serious-game-for-the-cognitive-functions-of-multiple-sclerosis-patients-100415814","NCT04694534","Remediation Program Via a \"Serious Game\" for the Cognitive Functions of Multiple Sclerosis Patients","e-SEP Cognition: Effectiveness of a Remediation Program Via a \"Serious Game\" on the Cognitive Functions of Multiple Sclerosis Patients: Controlled, Randomized, Multicentric Trial","E-SEP","Inclusion Criteria:\n\n* Relapsing-remitting or progressive multiple sclerosis people defined according to Mc Donald's criteria revised in 2005\n* Age between ≥ 18 and ≤ 65 years old\n* Cognitive complaint, with at least one deficient score at the initial neuropsychological examination (\\\u003C5th percentile of the reference group), one of the scores of which concerns at least one BICAMS test\n* Have not had a definite relapse for at least 6 weeks\n* Be at least 4 weeks away from a corticosteroid bolus\n* Lack of neuroleptic treatment\n* Patient with an Internet connection\n* Signed informed consent\n\nExclusion Criteria:\n\n* Severe cognitive deficit defined by obtaining a deficit score in more than six cognitive processes at the initial neuropsychological assessment.\n* Neuropsychological care\n* Inability to receive oral and written information\n* Inability to use the software (due in particular to motor and \u002F or sensory difficulties),\n* Neurological or psychiatric comorbidity, other than MS and anxiodepressive syndrome\n* Patient with severe anxiodepressive syndrome (BDI\\> 27)\n* Participation in an interventional study on cognitive functions\n* Patient under legal protection, guardianship or curatorship\n* Pregnant or breastfeeding women","65 Years",{"count":175,"type":21},150,[24],"The main goal of this study is to assess the effectiveness of a cognitive remediation program based on a \"serious game\" on the information processing speed evolution and the process of learning via episodic memory in multiple sclerosis patients.",[179,180,28],"Multiple Sclerosis","Memory",[182,183,184,185],"Multiple sclerosis","Serious game","Episodic memory learning capacities","Information processing speed capacities","2025-09-03",{"date":188,"type":42},"2025-09-04",{"date":190,"type":42},"2021-10-08",{"date":192,"type":21},"2027-03-01",{"name":194,"class":75},"Lille Catholic University",6,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":16,"sex":17,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":207,"phases":4,"briefSummary":208,"conditions":209,"keywords":233,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":50},"100469557","generation-victoria-cohort-2020s-a-statewide-longitudinal-cohort-study-of-victorian-children-and-their-parents-100469557","NCT05394363","Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents","Generation Victoria Cohort 2020s. A Statewide Longitudinal Cohort of Victorian Children and Their Parents","GenV","Inclusion Criteria (Children):\n\n* Birth date between 4th October 2021 and 3rd October 2023\n* Live at the time of recruitment\n* Residing in Victoria at the time of recruitment\n* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the child's behalf, who provides a signed and dated informed consent form (e.g. a parent\u002Fguardian)\n\nInclusion Criteria (Adults):\n\n* Be a parent or guardian of a child who meets the eligibility criteria above\n* Provide a signed and dated informed consent form or have a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.\n\nExclusion criteria:\n\n* Children who are deceased at the time of recruitment (i.e. still born or died after birth) and their parents\u002Fguardians\n* Families unable to provide informed consent in any of the languages available","1 Day",{"count":206,"type":21},150000,"OBSERVATIONAL","Generation Victoria (GenV) is a longitudinal, population-based study of Victorian children and their parents that will bring together data on a wide range of conditions ,exposures and outcomes. GenV blends study-collected, study-enhanced and linked data. It will be multi-purpose, supporting observational, interventional, health services and policy research within the same cohort. It is designed to address physical, mental and social issues experienced during childhood, as well as the antecedents of a wide range of diseases of ageing. It seeks to generate translatable evidence (prediction, prevention, treatments, services) to improve future wellbeing and reduce the future disease burden of children and adults.\n\nThe GenV Cohort 2020s is open to all children born over a two-year period, and their parents, residing in the state of Victoria Australia. The GenV Cohort 2020s is preceded by an Advance Cohort of children born between 5 Dec 2020 and 3 October 2021, and their parents. This comprises all families recruited at GenV's Vanguard hospital (Joan Kirner Women's and Children's) and at birthing hospitals throughout Victoria as GenV scaled up to commence recruiting for the GenV Cohort 2020s. The Advance Cohort have ongoing and full participation in GenV for their lifetime unless they withdraw but may have less complete data and biosamples.",[210,211,212,213,214,215,216,217,218,219,220,155,28,221,222,223,224,225,226,227,228,229,230,231,232],"Mental Health","Child Wellbeing","Infant Health","Child Health","Reproductive Health","Healthy Aging","Health Equity","Quality of Life","Social Determinants of Health","Environmental Exposure","Genetics","Child Development","Congenital Abnormalities","Disability","Injuries","Communicable Diseases","Noncommunicable Diseases","Physical Fitness","Diet","Obesity","Allergy and Immunology","Inflammation","Intergenerational Relations",[234,202,235,236,237,213,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,216,254,255,256,257,258,259,260,218,261,262],"Generation Victoria","Cohort Studies","Data Collection","Data Linkage","Midlife Health","Children","Infants","Family","Parents","Mothers","Fathers","Life course perspective","Population Health","Longitudinal Studies","Genetics, population","Demography","Epidemiology","Health Disparity","Minority Health","Vulnerable Populations","Clinical Trial","Randomized Controlled Trial","Pragmatic Clinical Trial","Health Services Research","Economic Models","Value of Life","Geographic Information Systems","Climate Change","Built Environment","2025-07-30",{"date":265,"type":42},"2025-08-03",{"date":267,"type":42},"2021-10-04",{"date":269,"type":21},"2033-10",{"name":271,"class":75},"Murdoch Childrens Research Institute",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":50},"100590998","interactive-virtual-occupational-safety-training-designed-for-home-healthcare-workers-100590998","NCT06974708","Interactive Virtual Occupational Safety Training Designed for Home Healthcare Workers","Interactive Virtual Occupational Safety Training Designed With and for Ohio Home Healthcare Workers and Agencies","Inclusion Criteria:\n\n* have no formal training in home safety, and\n* ≥18 years old, and\n* able to read and write in English.\n\nExclusion Criteria:\n\n* Participant in a prior study about home healthcare worker occupational safety training\n* Individuals who meet criteria for Pre-existing Conditions Related to Cybersickness (a set of 4 screening questions)",{"count":280,"type":21},24,[24],"Overview. The investigators will collect preliminary data on the extent to which the knowledge gained from the enhanced HH-VSTS transfers to a real-world environment. Following abbreviated use of the enhanced HH-VSTS, participants will perform a walk-through of a realistic environment to assess their learning.",[28],[285,286,287],"home healthcare","training","occupational safety","2025-05-13",{"date":290,"type":42},"2025-05-16",{"date":292,"type":42},"2025-04-17",{"date":294,"type":21},"2025-06-30",{"name":296,"class":75},"Ohio State University",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":50},"100552385","integrated-learning-support-system-based-on-immersive-simulated-training-for-nursing-students-100552385","NCT06472401","Integrated Learning Support System Based on Immersive Simulated Training for Nursing Students","Integrated Learning Support System Based on Immersive Simulated Training for Nursing Students: Randomized Controlled Trial","Inclusion Criteria:\n\n* Be aged ≥ 18 years old;\n* Students enrolled in the last two years of the undergraduate nursing course;\n* Students who have self-declared internet access in their homes to complete the course's online modules.\n\nExclusion Criteria:\n\n* Students who have previous training and\u002For professional experience in the health area;\n* Students who do not complete at least 75% of the workload of the proposed course.",{"count":305,"type":21},95,[24],"This study aims to evaluate the effectiveness of an Integrated Learning Support System (ILSS) in preparing undergraduate nursing students for immersive simulated training in managing drug-induced nephrotoxicity. The study hypothesizes that the ILSS, which accommodates different learning styles, will be more effective in reducing stress and anxiety compared to the standard learning model (SLM). The research will involve a parallel randomized controlled trial with 96 students from two Brazilian institutions. The students will be divided into control and experimental groups, with the latter using the ILSS in addition to SLM during preparation. The study will assess outcomes such as knowledge acquisition, skill development, and stress reduction using various instruments, including the Lasater Clinical Judgment Rubric and DASS-21. The study's findings aim to validate the ILSS as a tool to enhance learning outcomes and reduce stress and anxiety, thereby promoting better professional development and patient safety in nursing practice.",[309,28,310,311,312],"Simulation Training","Educational Technology","Nephrotoxicity","Physiological Stress","2024-07-29",{"date":315,"type":42},"2024-07-31",{"date":317,"type":21},"2024-08-01",{"date":319,"type":21},"2025-12",{"name":321,"class":75},"University of Brasilia",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":337,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":4},"100548799","work-package-3-education-for-icu-clinicians-in-basic-palliative-care-100548799","NCT06425692","Work Package 3 Education for ICU Clinicians in Basic Palliative Care","Enhancing Palliative Care in ICU (EPIC) - Work Package 3","Inclusion Criteria:\n\n* ≥18 years\n* ICU staff and participants of the EPIC intervention study (physician, nurse)\n* participants of patients and family workshops\n* agreement to participate in the study\n\nExclusion Criteria:\n\n* \\<18 years\n* rejection of study participation.",{"count":330,"type":21},500,[24],"The EPIC project aims at sustainably improving palliative care for seriously ill patients and their families in ICUs. To this aim, an interdisciplinary consortium is working together to provide a new practical palliative care model using telemedicine. The project is the first European intervention study on palliative care in the ICU using a systems- based approach with proactive patient identification, checklist and blended learning designed to meet the specific needs of ICU staff.\n\nEPIC's vision is to contribute to a change in awareness from a narrow focus on prolonging life to a more holistic approach to care.\n\nThe development of blended learning for intensive care staff is the task of Work Package (WP) 3. The aim is to improve the attitude, understanding and self-confidence of ICU staff. Blended learning is to be developed and implemented for this purpose. The aim is to teach the basics of palliative care on a cognitive, affective and psychomotor level.\n\nDue to the international character of the project, it is to be developed in English with subtitles in the local languages. In addition a workshop with patient and family advisors will be conducted.",[334,335,28,336],"ICU","Staff Attitude","Palliative Care, Patient Care",[338,339,340],"multi-center study","ICU staff","EU-Horizon","2024-05-21",{"date":343,"type":42},"2024-05-22",{"date":345,"type":21},"2024-09-01",{"date":347,"type":21},"2029-01-01",{"name":349,"class":75},"Heinrich-Heine University, Duesseldorf"]